Highly Effective Therapy Versus Escalation Approaches in Early Multiple Sclerosis What Is the Future of Multiple Sclerosis Treatment?

被引：9
作者：
Rjeily, Nicole Bou [1 ]
Mowry, Ellen M. [1 ,2 ]
Ontaneda, Daniel [3 ]
Carlson, Alise K. [3 ]
机构：
[1] Johns Hopkins Univ, Sch Med, Dept Neurol, 600 North Wolfe St,Pathol 627, Baltimore, MD 21287 USA
[2] Johns Hopkins Univ, Sch Med, Dept Epidemiol, 600 North Wolfe St,Pathol 627, Baltimore, MD 21287 USA
[3] Cleveland Clin, Mellen Ctr, 9500 Euclid Ave U10, Cleveland, OH 44195 USA
来源：
NEUROLOGIC CLINICS | 2024年 / 42卷 / 01期
基金：
美国国家卫生研究院;
关键词：
Multiple sclerosis; Relapsing-remitting multiple sclerosis; Disease-modifying therapy; Escalation therapy; Eary highly effective therapy; DISEASE-MODIFYING THERAPY; PLACEBO-CONTROLLED TRIAL; CONTROLLED PHASE-3; DOUBLE-BLIND; INTERFERON BETA-1A; NATURAL-HISTORY; ORAL BG-12; TERIFLUNOMIDE; ALEMTUZUMAB; DISABILITY;
D O I：
10.1016/j.ncl.2023.06.004
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
[No abstract available]
引用
收藏
页码：185 / 201
页数：17
相关论文
共 95 条
[1]   Comparison of Physician Therapeutic Inertia for Management of Patients With Multiple Sclerosis in Canada, Argentina, Chile, and Spain [J].
Almusalam, Noora ;
Oh, Jiwon ;
Terzaghi, Maria ;
Maurino, Jorge ;
Bakdache, Fabien ;
Montoya, Alonso ;
Caceres, Fernando ;
Saposnik, Gustavo .
JAMA NETWORK OPEN, 2019, 2 (07)
[2]  
Amato MP, 2022, MS treatment, V271, P11761
[3]   Updates and advances in multiple sclerosis neurotherapeutics [J].
Amin, Moein ;
Hersh, Carrie M. .
NEURODEGENERATIVE DISEASE MANAGEMENT, 2023, 13 (01) :47-70
[4]  
[Anonymous], 2019, Tecfidera (dimethyl fumarate)
[5]  
[Anonymous], 2021, Ruxience (rituximab-pvrr)
[6]  
[Anonymous], 2021, Bafiertam (monomethyl fumarate)
[7]  
[Anonymous], 2021, Betaseron (interferon beta-1b) [package insert]
[8]  
[Anonymous], 2022, Kesimpta (ofatumumab)
[9]  
[Anonymous], 2014, Plegridy (peginterferon beta-1a)
[10]  
[Anonymous], 2022, Briumvi (ublituximab-xiiy)
12345678910